{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:31:05Z","timestamp":1772166665496,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiotoxicity remains a dreaded complication for patients undergoing chemotherapy with human epidermal growth factor (HER)-2 receptor antagonists and anthracyclines. Though many studies have looked at racial disparities in heart failure patients, minimal data is present for the cardio-oncology population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We queried the echocardiogram database at a safety net hospital, defined by a high proportion of patients with Medicaid or no insurance, for patients who received HER2 receptor antagonists and\/or anthracyclines from January 2016 to December 2018. Patient demographics, clinical characteristics, and treatment outcomes were collected. Based on US census data in 2019, home ZIP codes were used to group patients into quartiles based on median annual household income. The primary end point studied was referral rate to cardiology for patients undergoing chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 149 patients who had echocardiograms and also underwent treatment with HER2 receptor antagonists and\/or anthracyclines, of which 70 (47.0%) were referred to the cardio-oncology program at our institution. Basic demographics were similar, but white patients were more likely to live in ZIP codes with higher income quartiles (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001). Comparing between racial groups, there was no statistical difference in the percentage of patients that had a reduction in ejection fraction (EF) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.75). There was no statistical difference between racial groups in the number of cardiology or oncology appointments attended, number of appointments cancelled, average number of echocardiograms received, additional cardiac imaging received. Black patients were more likely to receive ACEI\/ARB post chemotherapy (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047). A logistic regression model was created using race, age, gender, insurance, income quartile by home ZIP code, comorbidities (hypertension, hyperlipidemia, coronary artery disease, arrhythmia, diabetes mellitus, smoking, family history, age\u2009&gt;\u200965), procedures (coronary stents, cardiac surgery), medications pre-chemotherapy, cancer type, cancer stage, and chemotherapy. This model found that there was an increased referral rate among patients from higher income quartiles (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017 for quartile 3,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.049 for quartile 4), patients with a history of hypertension (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), and patients with breast cancer (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The results of this study suggest that patients of our cardio-oncology population at a safety net hospital receive the same level of surveillance and treatment, and develop drop in ejection fraction at similar rates regardless of their race. However, patients that reside in ZIP codes associated with higher income quartiles,\n                      <jats:underline>with hypertension, and with breast cancer,<\/jats:underline>\n                      are associated with increased rate of referral.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40959-020-00080-w","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T02:04:48Z","timestamp":1611540288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Healthcare disparities in cardio oncology: patients receive same level of surveillance regardless of race at a safety net hospital"],"prefix":"10.1186","volume":"7","author":[{"given":"Crystal B.","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj K.","family":"Dalsania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman A.","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"issue":"2","key":"80_CR1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.15420\/cfr.2017:16:1","volume":"3","author":"R Pudil","year":"2017","unstructured":"Pudil R. The future role of cardio-oncologists. Card Fail Rev. 2017;3(2):140\u20132.","journal-title":"Card Fail Rev"},{"key":"80_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.pharmthera.2016.09.009","volume":"168","author":"T Magdy","year":"2016","unstructured":"Magdy T, Burmeister BT, Burridge PW. Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: what is missing? Pharmacol Ther. 2016;168:113\u201325. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.09.009.","journal-title":"Pharmacol Ther"},{"issue":"7","key":"80_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2459\/JCM.0000000000000667","volume":"19","author":"C Cadeddu Dessalvi","year":"2018","unstructured":"Cadeddu Dessalvi C, Deidda M, Mele D, Bassareo PP, Esposito R, Santoro C, et al. Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention. J Cardiovasc Med. 2018;19(7):315\u201323.","journal-title":"J Cardiovasc Med"},{"issue":"2","key":"80_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s11764-014-0408-9","volume":"9","author":"A Qin","year":"2015","unstructured":"Qin A, Thompson CL, Silverman P. Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin. J Cancer Surviv. 2015;9(2):252\u20139.","journal-title":"J Cancer Surviv"},{"key":"80_CR5","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1136\/heartjnl-2012-303151","volume":"99","author":"A Farolfi","year":"2013","unstructured":"Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, et al. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart. 2013;99:634\u20139.","journal-title":"Heart."},{"issue":"4","key":"80_CR6","first-page":"1717","volume":"33","author":"D Naumann","year":"2013","unstructured":"Naumann D, Rusius V, Margiotta C, Nevill A, Carmichael A, Rea D, et al. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer. Anticancer Res. 2013;33(4):1717\u201320.","journal-title":"Anticancer Res"},{"issue":"3","key":"80_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/HCO.0000000000000619","volume":"34","author":"TS Polonsky","year":"2019","unstructured":"Polonsky TS, DeCara JM. Risk factors for chemotherapy-related cardiac toxicity. Curr Opin Cardiol. 2019 May;34(3):283\u20138. https:\/\/doi.org\/10.1097\/HCO.0000000000000619.","journal-title":"Curr Opin Cardiol"},{"key":"80_CR8","doi-asserted-by":"publisher","first-page":"e000116","DOI":"10.1136\/openhrt-2014-000116","volume":"1","author":"M Wasielewski","year":"2014","unstructured":"Wasielewski M, van Spaendonck-Zwarts KY, Westerink ND, Jongbloed JD, Postma A, Gietema JA, et al. Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy. Open Heart. 2014;1:e000116.","journal-title":"Open Heart"},{"issue":"18","key":"80_CR9","doi-asserted-by":"publisher","first-page":"e537","DOI":"10.1200\/JCO.2011.34.8052","volume":"29","author":"KE Shipman","year":"2011","unstructured":"Shipman KE, Arnold I. Case of epirubicin-induced cardiomyopathy in familial cardiomyopathy. J Clin Oncol. 2011;29(18):e537\u20138.","journal-title":"J Clin Oncol"},{"issue":"7","key":"80_CR10","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1093\/annonc\/mdr272","volume":"22","author":"AC Young","year":"2011","unstructured":"Young AC, Mercer B, Perren TJ, Dodwell D. Anthracycline-induced cardiomyopathy in siblings with early breast cancer. Ann Oncol. 2011;22(7):1692.","journal-title":"Ann Oncol"},{"issue":"44","key":"80_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005195","volume":"95","author":"Z Jawa","year":"2016","unstructured":"Jawa Z, Perez RM, Garlie L, Singh M, Qamar R, Khandheria BK, et al. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer. Medicine (Baltimore). 2016;95(44):e5195.","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"80_CR12","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1200\/JCO.2005.03.3472","volume":"24","author":"LA Newman","year":"2006","unstructured":"Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol. 2006 Mar 20;24(9):1342\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"80_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10549-018-4909-5","volume":"172","author":"AK Green","year":"2018","unstructured":"Green AK, Aviki EM, Matsoukas K, Patil S, Korenstein D, Blinder V. Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2018 Nov;172(2):247\u201363. https:\/\/doi.org\/10.1007\/s10549-018-4909-5.","journal-title":"Breast Cancer Res Treat"},{"issue":"27","key":"80_CR14","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.1200\/JCO.2005.12.633","volume":"23","author":"D Hershman","year":"2005","unstructured":"Hershman D, McBride R, Jacobson JS, Lamerato L, Roberts K, Grann VR, et al. Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol. 2005 Sep 20;23(27):6639\u201346.","journal-title":"J Clin Oncol"},{"issue":"9","key":"80_CR15","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/cncr.31260","volume":"124","author":"A Litvak","year":"2018","unstructured":"Litvak A, Batukbhai B, Russell SD, Tsai HL, Rosner GL, Jeter SC, et al. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. Cancer. 2018;124(9):1904\u201311.","journal-title":"Cancer."},{"issue":"2","key":"80_CR16","first-page":"196","volume":"96","author":"S Hasan","year":"2004","unstructured":"Hasan S, Dinh K, Lombardo F, Kark J. Doxorubicin cardiotoxicity in African Americans. J Natl Med Assoc. 2004 Feb;96(2):196\u20139.","journal-title":"J Natl Med Assoc"},{"issue":"8","key":"80_CR17","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jcmg.2018.06.005","volume":"11","author":"ML Henry","year":"2018","unstructured":"Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast Cancer patients. JACC Cardiovasc Imaging. 2018 Aug;11(8):1084\u201393. https:\/\/doi.org\/10.1016\/j.jcmg.2018.06.005.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"21","key":"80_CR18","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1161\/CIR.0000000000000534","volume":"136","author":"MR Carnethon","year":"2017","unstructured":"Carnethon MR, Pu J, Howard G, Albert MA, Anderson CAM, Bertoni AG, et al. Cardiovascular health in African Americans: A scientific statement from the American Heart Association. Circulation. 2017;136(21):e393\u2013423. https:\/\/doi.org\/10.1161\/CIR.0000000000000534.","journal-title":"Circulation"},{"issue":"8","key":"80_CR19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017 Mar 10;35(8):893\u2013911. https:\/\/doi.org\/10.1200\/JCO.2016.70.5400.","journal-title":"J Clin Oncol"},{"issue":"5","key":"80_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.breast.2010.02.001","volume":"19","author":"LJ Murraya","year":"2010","unstructured":"Murraya LJ, Ramakrishnan S, O\u2019Toole L, Manifold IH, Purohit OP, Coleman RE. Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery. Breast. 2010;19(5):339\u201344. https:\/\/doi.org\/10.1016\/j.breast.2010.02.001.","journal-title":"Breast"},{"issue":"4","key":"80_CR21","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1177\/1049909117727455","volume":"35","author":"KJ Wiskar","year":"2018","unstructured":"Wiskar KJ, Celi LA, McDermid RC, Walley KR, Russell JA, Boyd JH, et al. Patterns of palliative care referral in patients admitted with heart failure requiring mechanical ventilation. Am J Hosp Palliat Care. 2018;35(4):620\u20136. https:\/\/doi.org\/10.1177\/1049909117727455.","journal-title":"Am J Hosp Palliat Care"},{"issue":"12","key":"80_CR22","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S0828-282X(09)70528-8","volume":"25","author":"D Feldman","year":"2009","unstructured":"Feldman D, Xiao Y, Bernatsky S, Haggerty J, Leffondre K, Tousignant P, et al. Consultation with cardiologists for persons with new-onset chronic heart failure: a population-based study. Can J Cardiol. 2009;25(12):690\u20134.","journal-title":"Can J Cardiol"},{"issue":"5","key":"80_CR23","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/sj.bjc.6604909","volume":"100","author":"AL Jones","year":"2009","unstructured":"Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer. 2009;100(5):684\u201392.","journal-title":"Br J Cancer"},{"issue":"2","key":"80_CR24","first-page":"340","volume":"11","author":"MG Fradley","year":"2017","unstructured":"Fradley MG, Brown AC, Sheilds B, Viganego F, Damrongwatanasuk R, Patel AA, et al. Developing a comprehensive cardio-oncology program at a Cancer institute: the Moffitt Cancer Center experience. Oncol Rev. 2017;11(2):340.","journal-title":"Oncol Rev"},{"key":"80_CR25","doi-asserted-by":"publisher","first-page":"135819","DOI":"10.1155\/2012\/135819","volume":"2012","author":"S Dent","year":"2012","unstructured":"Dent S, Hopkins S, Graham N, Johnson C, Law A, Campbell M, et al. The experience of a multidisciplinary clinic in the management of early-stage breast cancer patients receiving trastuzumab therapy: an observational study. Cardiol Res Pract. 2012;2012:135819.","journal-title":"Cardiol Res Pract"},{"key":"80_CR26","first-page":"671232","volume":"2015","author":"J Sulpher","year":"2015","unstructured":"Sulpher J, Mathur S, Graham N, Crawley F, Turek M, Johnson C, et al. Clinical experience of patients referred to a multidisciplinary cardiac oncology clinic: an observational study. J Oncol. 2015;2015:671232.","journal-title":"J Oncol"},{"issue":"2","key":"80_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.canep.2011.10.012","volume":"36","author":"S Whitman","year":"2012","unstructured":"Whitman S, Orsi J, Hurlbert M. The racial disparity in breast cancer mortality in the 25 largest cities in the United States. Cancer Epidemiol. 2012;36(2):147\u201351.","journal-title":"Cancer Epidemiol"},{"issue":"7","key":"80_CR28","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1177\/000313481107700734","volume":"77","author":"D Keller","year":"2011","unstructured":"Keller D, Guilfoyle C, Sariego J. Geographical influence on racial disparity in breast cancer presentation in the United States. Am Surg. 2011;77(7):933\u20136.","journal-title":"Am Surg"},{"issue":"5","key":"80_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.2044","volume":"1","author":"N Downing","year":"2018","unstructured":"Downing N, Wang C, Gupta A, Wang Y, Nuti S, Ross J, Bernheim S, et al. Association of Racial and Socioeconomic Disparities with Outcomes among Patients Hospitalized with Acute Myocardial Infarction, heart failure, and pneumonia: an analysis of within- and between-hospital variation. JAMA Netw Open. 2018;1(5):e182044.","journal-title":"JAMA Netw Open"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-020-00080-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40959-020-00080-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-020-00080-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T02:06:47Z","timestamp":1611540407000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-020-00080-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,25]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["80"],"URL":"https:\/\/doi.org\/10.1186\/s40959-020-00080-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-28748\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-28748\/v2","asserted-by":"object"}]},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,25]]},"assertion":[{"value":"12 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures and protocols were approved by the Institutional Review Board at Temple University Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}